miRNA‑199b‑3p suppresses growth and progression of ovarian cancer via the CHK1/E‑cadherin/EMT signaling pathway by targeting ZEB1

Wei,Liqun; He,Yuanqi; Bi,Shuhong; Li,Xiaoxiao; Zhang,Jianzhong; Zhang,Shihong

doi:10.3892/or.2020.7895

miRNA‑199b‑3p suppresses growth and progression of ovarian cancer via the CHK1/E‑cadherin/EMT signaling pathway by targeting ZEB1

Authors:
- Liqun Wei
- Yuanqi He
- Shuhong Bi
- Xiaoxiao Li
- Jianzhong Zhang
- Shihong Zhang
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Weihai Municipal Hospital, Shandong University, Weihai, Shandong 264200, P.R. China
Published online on: December 11, 2020 https://doi.org/10.3892/or.2020.7895
Pages: 569-581
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is one of the most common gynecological malignancies and its pathogenesis and progression are regulated by multiple genes. MicroRNAs (miRNAs) are endogenous non‑coding RNAs that regulate body function by altering post‑transcriptional gene expression. Previous studies have suggested that miRNAs are closely associated with the pathogenesis and progression of several malignancies, including breast cancer, hepatocellular carcinoma and glioma, among others. Therefore, miRNAs are promising novel targets for the diagnosis, treatment and determination of prognostic factors in patients with ovarian cancer. In the present study, the role of miRNA‑133b‑3p in ovarian cancer progression and its possible mechanism of action were investigated. The results demonstrated that the expression of miRNA‑199b‑3p and zinc finger E‑box binding homeobox (ZEB)1 were increased in patients with ovarian cancer. The overall survival (OS) and disease‑free survival (DFS) of patients with ovarian cancer and high miRNA‑199b‑3p expression were prolonged compared with those of patients with low miRNA‑199b‑3p expression. Additionally, the OS and DFS of patients with ovarian cancer and low ZEB1 expression were longer compared with those of patients with high ZEB1 expression. Furthermore, miRNA‑199b‑3p overexpression reduced cell proliferation and promoted apoptosis in an in vitro model of ovarian cancer. miRNA‑199b‑3p overexpression also suppressed ZEB1 and checkpoint kinase 1 expression and induced E‑cadherin expression and epithelial‑to‑mesenchymal transition in this model. Furthermore, the effects of miRNA‑199b‑3p‑mediated apoptosis and migration were attenuated by ZEB1 and E‑cadherin, respectively. The results of the present study indicated that miRNA‑199b‑3p suppressed ovarian cancer progression by targeting ZEB1, which may represent a promising therapeutic target for ovarian cancer.

View Figures

View References

1	Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W and Martin LP: Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 148:507–514. 2018. View Article : Google Scholar : PubMed/NCBI
2	Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, Meng Y and Han W: Low dose decitabine combined with taxol and platinum chemotherapy to treat refractory/recurrent ovarian cancer: An open-label, single-arm, phase I/II study. Curr Protein Pept Sci. 16:329–336. 2015. View Article : Google Scholar : PubMed/NCBI
3	Liu GL, Yang HJ, Liu B and Liu T: Effects of microRNA-19b on the proliferation, apoptosis, and migration of Wilms' tumor cells via the PTEN/PI3K/AKT signaling pathway. J Cell Biochem. 118:3424–3434. 2017. View Article : Google Scholar : PubMed/NCBI
4	Gao J, Wu N, Liu X, Xia Y, Chen Y, Li S and Deng Z: MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1. Exp Ther Med. 15:5205–5214. 2018.PubMed/NCBI
5	Liang H, Zhao X, Wang C, Sun J, Chen Y, Wang G, Fang L, Yang R, Yu M, Gu Y and Shan H: Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer. Mol Cancer. 17:962018. View Article : Google Scholar : PubMed/NCBI
6	Wu DI, Liu L, Ren C, Kong D, Zhang P, Jin X, Wang T and Zhang G: Epithelial-mesenchymal interconversions and the regulatory function of the ZEB family during the development and progression of ovarian cancer. Oncol Lett. 11:1463–1468. 2016. View Article : Google Scholar : PubMed/NCBI
7	Sadlecki P, Jóźwicki J, Antosik P and Grabiec M: Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers. Tumour Biol. 40:10104283187848072018. View Article : Google Scholar : PubMed/NCBI
8	Mitra T, Prasad P, Mukherjee P, Chaudhuri SR and Chatterji U: Stemness and chemoresistance are imparted to the OC cells through TGFβ1 driven EMT. J Cell Biochem. 119:5775–5787. 2018. View Article : Google Scholar : PubMed/NCBI
9	Leng R, Liao G, Wang H, Kuang J and Tang L: Rac1 expression in epithelial ovarian cancer: Effect on cell EMT and clinical outcome. Med Oncol. 32:3292015. View Article : Google Scholar : PubMed/NCBI
10	Weingarten C, Jenudi Y, Tshuva RY, Moskovich D, Alfandari A, Hercbergs A, Davis PJ, Ellis M and Ashur-Fabian O: The interplay between epithelial-mesenchymal transition (EMT) and the thyroid hormones-αvβ3 axis in ovarian cancer. Horm Cancer. 9:22–32. 2018. View Article : Google Scholar : PubMed/NCBI
11	Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, et al: Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 15:1202017. View Article : Google Scholar : PubMed/NCBI
12	Koshizuka K, Hanazawa T, Kikkawa N, Arai T, Okato A, Kurozumi A, Kato M, Katada K, Okamoto Y and Seki N: Regulation of ITGA3 by the anti-tumor miR-199 family inhibits cancer cell migration and invasion in head and neck cancer. Cancer Sci. 108:1681–1692. 2017. View Article : Google Scholar : PubMed/NCBI
13	Blaha RZ, Arnett AB, Kirkwood MW, Taylor HG, Stancin T, Brown TM and Wade SL: Factors influencing attrition in a multisite, randomized, clinical trial following traumatic brain injury in adolescence. J Head Trauma Rehabil. 30:E33–E40. 2015. View Article : Google Scholar : PubMed/NCBI
14	Rochet N, Lindel K, Katayama S, Schubert K, Herfarth K, Schneeweiss A, Sohn C, Harms W and Debus J: Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer: Four-year outcomes. Strahlenther Onkol. 191:582–589. 2015. View Article : Google Scholar : PubMed/NCBI
15	Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK and Diamond JR: Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One. 9:e865322014. View Article : Google Scholar : PubMed/NCBI
16	Záveský L, Jandáková E, Weinberger V, Minář L, Hanzíková V, Dušková D, Drábková LZ, Svobodová I and Hořínek A: Ascites-derived extracellular microRNAs as potential biomarkers for ovarian cancer. Reprod Sci. 26:510–522. 2018. View Article : Google Scholar : PubMed/NCBI
17	Loginov VI, Pronina IV, Burdennyy AM, Filippova EA, Kazubskaya TP, Kushlinsky DN, Utkin DO, Khodyrev DS, Kushlinskii NE, Dmitriev AA and Braga EA: Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis. Gene. 662:28–36. 2018. View Article : Google Scholar : PubMed/NCBI
18	Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, et al: Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 116:117–125. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yu X, Wang Y, Qiu H, Song H, Feng D, Jiang Y, Deng S, Meng H and Geng J: AEG-1 contributes to metastasis in hypoxia-related ovarian cancer by modulating the HIF-1alpha/NF-kappaB/VEGF pathway. Biomed Res Int. 2018:31456892018. View Article : Google Scholar : PubMed/NCBI
20	Xu LJ, Duan Y, Wang P and Yin HQ: MiR-199b-5p promotes tumor growth and metastasis in cervical cancer by down-regulating KLK10. Biochem Biophys Res Commun. 503:556–563. 2018. View Article : Google Scholar : PubMed/NCBI
21	Mao M, Zheng X, Jin B, Zhang F, Zhu L and Cui L: Effects of CD44 and E-cadherin overexpression on the proliferation, adhesion and invasion of ovarian cancer cells. Exp Ther Med. 14:5557–5563. 2017.PubMed/NCBI
22	Wang YP, Wang QY, Li CH and Li XW: COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. Chem Biol Interact. 292:24–29. 2018. View Article : Google Scholar : PubMed/NCBI
23	Huang HN, Huang WC, Lin CH, Chiang YC, Huang HY and Kuo KT: Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Hum Pathol. 45:2318–2325. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Ma J, Shen H, Wang C, Sun Y, Howell SB and Lin X: Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncol Rep. 32:2150–2158. 2014. View Article : Google Scholar : PubMed/NCBI
25	Portune KJ, Benítez-Páez A, Del Pulgar EM, Cerrudo V and Sanz Y: Gut microbiota, diet, and obesity-related disorders-The good, the bad, and the future challenges. Mol Nutr Food Res. 61:2017. View Article : Google Scholar : PubMed/NCBI